We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sharpless Says Questions Remain as FDA Moves to Streamline Insulin Approvals
Sharpless Says Questions Remain as FDA Moves to Streamline Insulin Approvals
Acting FDA Commissioner Ned Sharpless said the agency is inching closer to bringing cheaper insulins to the market but that critical regulatory questions remain.